An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Horizon Therapeutics plc Announces Scientific Collaboration with Leading Research Institution to Advance Research in Autoimmunity and Inflammation
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Horizon Therapeutics has announced a multi-year collaboration with Johns Hopkins University School of Medicine to explore new therapies for autoimmune and inflammatory diseases. The partnership will initially focus on immunometabolism, aiming to identify metabolic pathways that contribute to conditions like myositis. This collaboration coincides with Horizon's expansion in Maryland, where it will become the first tenant at the Alexandria Center at Traville Gateway, promoting job growth and new therapeutic developments.
Positive
Collaboration with Johns Hopkins University enhances research capabilities in autoimmune diseases.
Focus on immunometabolism may lead to novel therapeutic targets.
Expansion in Maryland supports job growth and new medicine development.
Negative
None.
DUBLIN--(BUSINESS WIRE)--
Horizon Therapeutics plc today announced that it has entered a multi-year scientific collaboration with Johns Hopkins University School of Medicine to identify new disease targets and develop therapies for patients with serious autoimmune and inflammatory conditions. The initial focus is the emerging field of immunometabolism, the study of metabolic processes in the body, that when dysregulated, can drive autoimmunity and inflammation. This is the first project in the collaboration, with additional projects to follow.
“Collaboration is essential to move science forward and we are very pleased to begin working with Johns Hopkins University,” said Elizabeth H.Z. Thompson, Ph.D., executive vice president, research and development, Horizon. “By combining Johns Hopkins capabilities in pre-clinical research with Horizon’s expertise in autoimmunity, our teams will advance translational and research efforts to address the unique needs of different patient populations.”
Horizon’s research scientists, in collaboration with Johns Hopkins University School of Medicine experts, aim to identify novel metabolic pathways that lead to chronic inflammation and autoimmunity in different subsets of myositis patients. This deeper pathway knowledge will then be used to identify novel drug targets that may be suitable for discovery of new medicines.
The collaboration comes as Horizon is increasing its presence in Maryland and will be the first tenant at the Alexandria Center® at Traville Gateway campus in Rockville, Maryland. When completed, the state-of-the-art facility will support job growth and drive The Company’s continued efforts to develop new medicines.
“As Horizon deepens our footprint in the Maryland area, we believe this collaboration will bolster the world-class scientific thinking and technical capabilities that are found in the Maryland life sciences ecosystem,” said Robert Stoffel, Ph.D., vice president, research, Horizon. “Working hand-in-hand with experts at Johns Hopkins University will allow our teams to better understand the biology of diseases we are investigating and identify new pre-clinical targets that could lead to novel therapeutics.”
About Horizon
Horizon is a global biotechnology company focused on the discovery, development and commercialization of medicines that address critical needs for people impacted by rare, autoimmune and severe inflammatory diseases. Our pipeline is purposeful: We apply scientific expertise and courage to bring clinically meaningful therapies to patients. We believe science and compassion must work together to transform lives. For more information on how we go to incredible lengths to impact lives, visit www.horizontherapeutics.com and follow us on Twitter, LinkedIn, Instagram and Facebook.
What is the recent collaboration announced by Horizon Therapeutics?
Horizon Therapeutics announced a multi-year collaboration with Johns Hopkins University to develop therapies for autoimmune and inflammatory diseases, focusing initially on immunometabolism.
How will the collaboration with Johns Hopkins University impact Horizon Therapeutics?
The collaboration aims to identify novel drug targets and bolster Horizon's research efforts in autoimmune diseases, enhancing its therapeutic pipeline.
Where is Horizon Therapeutics expanding its operations?
Horizon is expanding its operations in Maryland and will be the first tenant at the Alexandria Center at Traville Gateway in Rockville.
What is the focus of the scientific collaboration between Horizon and Johns Hopkins?
The collaboration focuses on exploring metabolic processes related to autoimmunity and inflammation, specifically targeting chronic inflammation pathways.
What are the potential benefits of the Horizon and Johns Hopkins collaboration?
The collaboration could lead to the discovery of new medicines targeting autoimmune conditions, improving patient outcomes.
